197 related articles for article (PubMed ID: 32648699)
1. A Human Liver-on-a-Chip Platform for Modeling Nonalcoholic Fatty Liver Disease.
Lasli S; Kim HJ; Lee K; Suurmond CE; Goudie M; Bandaru P; Sun W; Zhang S; Zhang N; Ahadian S; Dokmeci MR; Lee J; Khademhosseini A
Adv Biosyst; 2019 Aug; 3(8):e1900104. PubMed ID: 32648699
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Human Liver Model of Nonalcoholic Steatohepatitis by Coculturing Hepatocytes, Endothelial Cells, and Kupffer Cells.
Suurmond CE; Lasli S; van den Dolder FW; Ung A; Kim HJ; Bandaru P; Lee K; Cho HJ; Ahadian S; Ashammakhi N; Dokmeci MR; Lee J; Khademhosseini A
Adv Healthc Mater; 2019 Dec; 8(24):e1901379. PubMed ID: 31746151
[TBL] [Abstract][Full Text] [Related]
3. Investigating Nonalcoholic Fatty Liver Disease in a Liver-on-a-Chip Microfluidic Device.
Gori M; Simonelli MC; Giannitelli SM; Businaro L; Trombetta M; Rainer A
PLoS One; 2016; 11(7):e0159729. PubMed ID: 27438262
[TBL] [Abstract][Full Text] [Related]
4. Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis.
Pingitore P; Sasidharan K; Ekstrand M; Prill S; Lindén D; Romeo S
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30986904
[TBL] [Abstract][Full Text] [Related]
5. Quercetin and hydroxytyrosol as modulators of hepatic steatosis: A NAFLD-on-a-chip study.
Gori M; Giannitelli SM; Zancla A; Mozetic P; Trombetta M; Merendino N; Rainer A
Biotechnol Bioeng; 2021 Jan; 118(1):142-152. PubMed ID: 32889748
[TBL] [Abstract][Full Text] [Related]
6. Modeling Human Nonalcoholic Fatty Liver Disease (NAFLD) with an Organoids-on-a-Chip System.
Wang Y; Wang H; Deng P; Tao T; Liu H; Wu S; Chen W; Qin J
ACS Biomater Sci Eng; 2020 Oct; 6(10):5734-5743. PubMed ID: 33320545
[TBL] [Abstract][Full Text] [Related]
7. Human Nonalcoholic Steatohepatitis on a Chip.
Freag MS; Namgung B; Reyna Fernandez ME; Gherardi E; Sengupta S; Jang HL
Hepatol Commun; 2021 Feb; 5(2):217-233. PubMed ID: 33553970
[TBL] [Abstract][Full Text] [Related]
8. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice.
Hong Y; Choi SI; Hong E; Kim GH
J Food Sci; 2020 Jul; 85(7):2216-2226. PubMed ID: 32579753
[TBL] [Abstract][Full Text] [Related]
9. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
Zhang J; Du H; Shen M; Zhao Z; Ye X
J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
[TBL] [Abstract][Full Text] [Related]
10. Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply.
Du K; Li S; Li C; Li P; Miao C; Luo T; Qiu B; Ding W
Acta Biomater; 2021 Oct; 134():228-239. PubMed ID: 34265474
[TBL] [Abstract][Full Text] [Related]
11. Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism.
He M; Wang C; Long XH; Peng JJ; Liu DF; Yang GY; Jensen MD; Zhang LL
World J Gastroenterol; 2020 Mar; 26(10):1029-1041. PubMed ID: 32205994
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interplay between human MSCs and HUVECs in 3D spheroids laden in collagen/fibrin hydrogels for bone tissue engineering.
Heo DN; Hospodiuk M; Ozbolat IT
Acta Biomater; 2019 Sep; 95():348-356. PubMed ID: 30831326
[TBL] [Abstract][Full Text] [Related]
13. Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro.
Murakami S; Ono A; Kawasaki A; Takenaga T; Ito T
Amino Acids; 2018 Sep; 50(9):1279-1288. PubMed ID: 29946793
[TBL] [Abstract][Full Text] [Related]
14. SGL 121 Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism Through AMPK Signaling Pathway.
Kim DE; Chang BY; Jeon BM; Baek JI; Kim SC; Kim SY
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630596
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
[TBL] [Abstract][Full Text] [Related]
16. An oxygen-permeable spheroid culture system for the prevention of central hypoxia and necrosis of spheroids.
Anada T; Fukuda J; Sai Y; Suzuki O
Biomaterials; 2012 Nov; 33(33):8430-41. PubMed ID: 22940219
[TBL] [Abstract][Full Text] [Related]
17. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
18. Optimization of Albumin Secretion and Metabolic Activity of Cytochrome P450 1A1 of Human Hepatoblastoma HepG2 Cells in Multicellular Spheroids by Controlling Spheroid Size.
Nishikawa T; Tanaka Y; Nishikawa M; Ogino Y; Kusamori K; Mizuno N; Mizukami Y; Shimizu K; Konishi S; Takahashi Y; Takakura Y
Biol Pharm Bull; 2017; 40(3):334-338. PubMed ID: 28250275
[TBL] [Abstract][Full Text] [Related]
19. Artemisia capillaris formula inhibits hepatic steatosis via an miR‑122‑induced decrease in fatty acid synthase expression in vivo and in vitro.
Liu L; Zhao J; Li Y; Wan Y; Lin J; Shen A; Xu W; Li H; Zhang Y; Xu J; Peng J; Hong Z
Mol Med Rep; 2016 Jun; 13(6):4751-8. PubMed ID: 27081834
[TBL] [Abstract][Full Text] [Related]
20. Design and fabrication of a liver-on-a-chip platform for convenient, highly efficient, and safe in situ perfusion culture of 3D hepatic spheroids.
Ma LD; Wang YT; Wang JR; Wu JL; Meng XS; Hu P; Mu X; Liang QL; Luo GA
Lab Chip; 2018 Aug; 18(17):2547-2562. PubMed ID: 30019731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
